<DOC>
	<DOCNO>NCT00151632</DOCNO>
	<brief_summary>The prevention graft rejection liver transplantation benefit nowadays variety newly develop immunosuppressive agent . This allow flexible individualized immunoprophylaxis give opportunity reduce long-term side effect ( hypertension , renal failure , diabetes , etc . ) immunosuppression . The purpose study evaluate , liver transplant patient , low dos tacrolimus , give combination mycophenolate mofetil , result low rate long-term side effect without increase rate graft rejection .</brief_summary>
	<brief_title>Reduction Tacrolimus Dose Association With Mycophenolate Mofetil After Liver Transplantation</brief_title>
	<detailed_description>Tacrolimus mycophenolate mofetil currently approve immunosuppressive agent prevention acute chronic rejection liver transplantation . Adverse effect tacrolimus dose-dependent appear early onset treatment . To prevent side effect , propose combine reduce dos tacrolimus another immunosuppressant , i.e . mycophenolate mofetil , administer usual dos . This study evaluate interest combination , subsequently , pharmacokinetics mycophenolate mofetil therapeutic context . Patients undergo liver transplantation randomize tacrolimus normal dos combination tacrolimus half dos mycophenolate mofetil . A corticotherapy associate group . The safety evaluate number graft rejection day 1 transplantation week 48 ; onset complication ( hypertension , renal failure , diabetes , etc . ) allow evaluate efficacy treatment schedule .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Adults 18 year age Primary liver transplantation Immunosuppressive treatment associate tacrolimus steroid low dos ( &lt; 20 mg/d ) Written informed consent Non Pregnancy ineffective contraception Immunosuppressive treatment Blood group incompatibility donor Autoimmune hepatitis Fulminant hepatitis Primary sclerosing cholangitis Combined transplantation Reduced liver Living donor Treated hypertension and/or diastolic pressure ≥ 90 mmHg and/or systolic pressure ≥ 140 mmHg , Acute chronic renal failure ( creatininemia ≥ 130 μmol/L ) transplantation Treated diabetes and/or fast glycemia ≥ 7 mmol/L Treated hypercholesterolemia and/or cholesterolemia ≥ 7 mmol/L postoperative creatininemia ≥ 200 μmol/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Liver transplantation</keyword>
	<keyword>Acute graft rejection</keyword>
	<keyword>Treatment combination</keyword>
</DOC>